K KNOA PHARMA
LIVE

Serial Number

97132159

Owner

Purdue Pharma L.P.

Attorney

FARA S. SUNDERJI

Filing Date

Nov 18, 2021

Add to watchlist:

No watchlists yet
View on USPTO

K KNOA PHARMA Trademark

Serial Number: 97132159

K KNOA PHARMA is a trademark filed by Purdue Pharma L.P. on November 18, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Purdue Pharma L.P.

One Stamford Forum
Stamford, CT 06901

Entity Type: 13

Trademark Details

Filing Date

November 18, 2021

Registration Date

Not Registered

Published for Opposition

May 2, 2023

Goods & Services

A house mark for a full line of pharmaceuticals; pharmaceuticals for use in the treatment of central nervous system disorders, pain, opioid overdose, opioid reversal, opioid use disorders, interstitial cystitis/bladder pain syndrome (IC/BPS), Overactive Bladder (OAB), Alcohol Use Disorder, Substance Use Disorder, sleep disorders including Insomnia Associated with Alcohol Cessation (IAAC), anaphylaxis; pharmaceuticals for use in the treatment of oncology conditions, specifically glioblastoma multiforme (GBM), non Hodgkin lymphoma, solid tumors, melanoma, chronic myelogenous leukemia, hemato-oncology, refractory/relapsed malignancies, alone or in combination with other agents; analgesics; pharmaceuticals, namely, opioid antagonists; syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; syringes filled with opioid antagonists; injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectors filled with opioid antagonists; injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectable pharmaceuticals, namely, opioid antagonists

Pharmaceutical research and development

Filing History

SOU TEAS EXTENSION RECEIVED
Jun 3, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 20, 2025 EXRA
SOU EXTENSION 3 GRANTED
Nov 19, 2025 EX3G
SOU EXTENSION 3 FILED
Nov 19, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 19, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 6, 2025 EXRA
SOU EXTENSION 2 GRANTED
May 6, 2025 EX2G
SOU EXTENSION 2 FILED
May 5, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
May 5, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 7, 2024 EXRA
SOU EXTENSION 1 GRANTED
Oct 7, 2024 EX1G
SOU EXTENSION 1 FILED
Oct 7, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 7, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 4, 2024 NOAM
TTAB RELEASE CASE TO TRADEMARKS
Apr 12, 2024 TMBN
OPPOSITION TERMINATED NO. 999999
Apr 12, 2024 OP.T
OPPOSITION DISMISSED NO. 999999
Apr 12, 2024 OP.D
OPPOSITION INSTITUTED NO. 999999
Jun 1, 2023 OP.I
OPPOSITION PAPERS RECEIVED AT TTAB
Jun 1, 2023 OPPF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 2, 2023 NPUB
PUBLISHED FOR OPPOSITION
May 2, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 12, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 27, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 16, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 16, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 16, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 16, 2023 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Mar 7, 2023 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Dec 27, 2022 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 14, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 7, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 7, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 7, 2022 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Jun 14, 2022 GPRN
PRIORITY ACTION E-MAILED
Jun 14, 2022 GPRA
PRIORITY ACTION WRITTEN
Jun 14, 2022 CPRA
ASSIGNED TO EXAMINER
Jun 7, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 23, 2021 NWOS
NEW APPLICATION ENTERED
Nov 22, 2021 NWAP